SCHEMBL2274040

SCHEMBL2274040

CC(=O)Oc1ccc(/C=C/C(=O)Nc2cc(Oc3ccccc3)ccc2C(=O)OC(C)(C)C)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.46
NPC1 O15118 4/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
ALDH1A1 P00352 2/20 0.46
LMNA P02545 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
SMN1; SMN2 Q16637 4/20 0.45
MAPT P10636 3/20 0.45
TRPA1 O75762 1/20 0.45
MCHR1 Q99705 1/20 0.41
SRD5A2 P31213 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
TRPV1 Q8NER1 2/20 0.40
TNIK Q9UKE5 1/20 0.40
MMP1 P03956 3/20 0.40
MMP2 P08253 3/20 0.40
MMP9 P14780 3/20 0.40
AKR1C3 P42330 1/20 0.40
AKR1C2 P52895 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2274043 1.00 RAB9A (0.46) RAB9ANPC1MEN1KMT2AALDH1A1
SCHEMBL2276453 0.88 TRPA1 (0.58) RAB9ANPC1MEN1KMT2AALDH1A1
SCHEMBL2276457 0.88 TRPA1 (0.58) RAB9ANPC1MEN1KMT2AALDH1A1
SCHEMBL2273849 0.85 ALDH1A1 (0.58) RAB9ANPC1MEN1KMT2AALDH1A1
SCHEMBL2273855 0.85 ALDH1A1 (0.58) RAB9ANPC1MEN1KMT2AALDH1A1
SCHEMBL14428191 0.83 RAB9A (0.47) RAB9ANPC1MEN1KMT2AALDH1A1
SCHEMBL2270181 0.78 TRPA1 (0.60) RAB9ANPC1MEN1KMT2AALDH1A1
SCHEMBL2270176 0.78 TRPA1 (0.60) RAB9ANPC1MEN1KMT2AALDH1A1
SCHEMBL2278133 0.76 TRPA1 (0.62) RAB9ANPC1MEN1KMT2AALDH1A1
SCHEMBL2278127 0.76 TRPA1 (0.62) RAB9ANPC1MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 RAB9A 2238/4885NPC1 4836/4885MEN1 3105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.